INTRODUCTION: It is unclear which antibiotic regimen provides the best prophylaxis against surgical site infection (SSI) in patients undergoing hip and knee surgery. QUESTIONS/PURPOSES: Therefore, we determined whether dual antibiotic prophylaxis (1) reduced the rate of SSI compared to single antibiotic prophylaxis and (2) altered the microbiology of SSI. METHODS: We retrospectively reviewed 1828 primary THAs and TKAs performed between September 1, 2008 and December 31, 2010. We divided patients into two groups: (1) those who received a dual prophylactic antibiotic regimen of cefazolin and vancomycin (unless allergy), or (2) received cefazolin (unless allergy) as the sole prophylactic antibiotic. There were 701 males and 1127 females with an average age of 56 years (range, 15–97 years). We limited followup to 1 year, presuming subsequent infections were not related to the initial surgery. RESULTS: During this period, there were 22 SSIs (1.2%). The infection rates for dual antibiotic prophylaxis compared to a single antibiotic regimen were 1.1% and 1.4%, respectively. Of 1328 patients treated with dual antibiotic prophylaxis, only one (0.08%) SSI was culture positive for methicillin resistant Staphylococcus aureus (MRSA), while four of 500 patients (0.8%) receiving only cefazolin prophylaxis had culture positive MRSA infection at the time of reoperation. CONCLUSION: The addition of vancomycin as a prophylactic antibiotic agent apparently did not reduce the rate of SSI compared to cefazolin alone. Use of vancomycin in addition to cefazolin appeared to reduce the incidence of MRSA infections; however, the number needed to treat to prevent a single MRSA infection was very high. LEVEL OF EVIDENCE: Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
INTRODUCTION: It is unclear which antibiotic regimen provides the best prophylaxis against surgical site infection (SSI) in patients undergoing hip and knee surgery. QUESTIONS/PURPOSES: Therefore, we determined whether dual antibiotic prophylaxis (1) reduced the rate of SSI compared to single antibiotic prophylaxis and (2) altered the microbiology of SSI. METHODS: We retrospectively reviewed 1828 primary THAs and TKAs performed between September 1, 2008 and December 31, 2010. We divided patients into two groups: (1) those who received a dual prophylactic antibiotic regimen of cefazolin and vancomycin (unless allergy), or (2) received cefazolin (unless allergy) as the sole prophylactic antibiotic. There were 701 males and 1127 females with an average age of 56 years (range, 15–97 years). We limited followup to 1 year, presuming subsequent infections were not related to the initial surgery. RESULTS: During this period, there were 22 SSIs (1.2%). The infection rates for dual antibiotic prophylaxis compared to a single antibiotic regimen were 1.1% and 1.4%, respectively. Of 1328 patients treated with dual antibiotic prophylaxis, only one (0.08%) SSI was culture positive for methicillin resistant Staphylococcus aureus (MRSA), while four of 500 patients (0.8%) receiving only cefazolin prophylaxis had culture positive MRSA infection at the time of reoperation. CONCLUSION: The addition of vancomycin as a prophylactic antibiotic agent apparently did not reduce the rate of SSI compared to cefazolin alone. Use of vancomycin in addition to cefazolin appeared to reduce the incidence of MRSA infections; however, the number needed to treat to prevent a single MRSA infection was very high. LEVEL OF EVIDENCE: Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
Authors: David H Kim; Maureen Spencer; Susan M Davidson; Ling Li; Jeremy D Shaw; Diane Gulczynski; David J Hunter; Juli F Martha; Gerald B Miley; Stephen J Parazin; Pamela Dejoie; John C Richmond Journal: J Bone Joint Surg Am Date: 2010-07-07 Impact factor: 5.284
Authors: Mark A Malangoni; William G Cheadle; Thomas F Dodson; Pascal M C E Dohmen; David Jones; Kushagra Katariya; Shyam Kolvekar; Joshua A Urban Journal: Surg Infect (Larchmt) Date: 2006 Impact factor: 2.150
Authors: Kevin J Bozic; Steven M Kurtz; Edmund Lau; Kevin Ong; Thomas P Vail; Daniel J Berry Journal: J Bone Joint Surg Am Date: 2009-01 Impact factor: 5.284
Authors: Minos E Tyllianakis; Athanasios Ch Karageorgos; Markos N Marangos; Alkis G Saridis; Elias E Lambiris Journal: J Arthroplasty Date: 2010-04-08 Impact factor: 4.757
Authors: Jacques Merrer; Laetitia Desbouchages; Valérie Serazin; Jimmy Razafimamonjy; François Pauthier; Michel Leneveu Journal: Infect Control Hosp Epidemiol Date: 2006-11-21 Impact factor: 3.254
Authors: Raymond J Lynch; Michael J Englesbe; Lisa Sturm; Amira Bitar; Karn Budhiraj; Sandeep Kolla; Yuliya Polyachenko; Mary G Duck; Darrell A Campbell Journal: Am J Med Qual Date: 2009 Jan-Feb Impact factor: 1.852
Authors: Kevin J Bozic; Steven M Kurtz; Edmund Lau; Kevin Ong; Vanessa Chiu; Thomas P Vail; Harry E Rubash; Daniel J Berry Journal: Clin Orthop Relat Res Date: 2009-06-25 Impact factor: 4.176
Authors: Catherine Liu; Anthony Kakis; Amy Nichols; Michael D Ries; Thomas P Vail; Kevin J Bozic Journal: Clin Orthop Relat Res Date: 2014-01 Impact factor: 4.176
Authors: Eduard Tornero; Sebastian García-Ramiro; Juan C Martínez-Pastor; Guillem Bori; Jordi Bosch; Laura Morata; Marta Sala; Misericordia Basora; Josep Mensa; Alex Soriano Journal: Antimicrob Agents Chemother Date: 2014-11-17 Impact factor: 5.191
Authors: Timothy L Tan; Bryan D Springer; John A Ruder; Michael R Ruffolo; Antonia F Chen Journal: Clin Orthop Relat Res Date: 2016-07 Impact factor: 4.176
Authors: P Maxwell Courtney; Christopher M Melnic; Zachary Zimmer; Jason Anari; Gwo-Chin Lee Journal: Clin Orthop Relat Res Date: 2015-07 Impact factor: 4.176